VVOS — Vivos Therapeutics Balance Sheet
0.000.00%
- $18.61m
- $24.42m
- $15.03m
Annual balance sheet for Vivos Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 18.2 | 24 | 3.52 | 1.64 | 6.26 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1.52 | 1.2 | 0.457 | 0.202 | 0.43 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 20.4 | 27.3 | 5.42 | 2.46 | 7.47 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.872 | 2.83 | 4.78 | 4.7 | 4.38 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 25.3 | 33.7 | 13.7 | 10.7 | 15.3 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.82 | 7.51 | 6.81 | 7.29 | 4.98 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8.41 | 8.15 | 8.92 | 10.3 | 7.33 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 16.9 | 25.5 | 4.8 | 0.411 | 7.95 |
| Total Liabilities & Shareholders' Equity | 25.3 | 33.7 | 13.7 | 10.7 | 15.3 |
| Total Common Shares Outstanding |